MINNEAPOLIS--(BUSINESS WIRE)--VigiLanz, a digital healthcare technology company headquartered in Minneapolis, announced today that its real-time clinical surveillance and software-as-a-service (SaaS) platform sent notifications through their software to thousand of clinicians across the U.S. on the latest superbug, also known as Carbapenem-Resistant Enterobacteriaceae (CRE). The antibiotic-resistant bacteria was found on hard-to-clean endoscopic devices.
“Our nimble software affords us the opportunity to alert customers in real-time when there is an outbreak, and immediate action is required to prevent infection spreading,” said Stacy Pur, Vice President for Clinical Decision Support. "When infections enter a healthcare facility, its imperative clinicians act quickly to protect the patients, staff and visitors. Once identified, clinicians can isolate and treat patients to minimize the risk of a potentially fatal infection spreading throughout hospital or the general public.”
An example of the posted alert VigiLanz sent to its hospital clinicians is below:
|VIGILANZ NEWS SCANNER: CRE|
A CRE associated outbreak is in the news. VigiLanz
VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, leading provider of clinical decision support and intelligence software solutions for hospitals. The company was founded by David Goldsteen, M.D. and David Klass, M.D. in 2001. VigiLanz supports a large and growing community of hospital quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to patient care. VigiLanz is helping transform 21st century health care and assisting emerging Accountable Care Organizations better manage patient communities through real-time clinical information.